NRG-GI005

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

Principal Investigator

Van Morris, MD

Status

Disease Site

Gastrointestinal [GI] Colorectal

Phase

II/III

Developmental Therapeutics

No

Primary Objective

Phase II – To compare the rate of ctDNA clearance in “ctDNA detected” patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer.

Phase III – To compare recurrence-free survival (RFS) in “ctDNA detected” patients treated with or without adjuvant chemotherapy following resection of state IIA colon cancer.

Patient Population

Patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer

Target Accrual

1408